These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 15090736)

  • 1. Brostallicin: a new concept in minor groove DNA binder development.
    Broggini M; Marchini S; Fontana E; Moneta D; Fowst C; Geroni C
    Anticancer Drugs; 2004 Jan; 15(1):1-6. PubMed ID: 15090736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione.
    Geroni C; Marchini S; Cozzi P; Galliera E; Ragg E; Colombo T; Battaglia R; Howard M; D'Incalci M; Broggini M
    Cancer Res; 2002 Apr; 62(8):2332-6. PubMed ID: 11956092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity.
    Lorusso D; Mainenti S; Pietragalla A; Ferrandina G; Foco G; Masciullo V; Scambia G
    Expert Opin Investig Drugs; 2009 Dec; 18(12):1939-46. PubMed ID: 19938904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
    Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
    Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytotoxic alpha-halogenoacrylic derivatives of distamycin A and congeners.
    Beria I; Baraldi PG; Cozzi P; Caldarelli M; Geroni C; Marchini S; Mongelli N; Romagnoli R
    J Med Chem; 2004 May; 47(10):2611-23. PubMed ID: 15115402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin.
    Sabatino MA; Geroni C; Ganzinelli M; Ceruti R; Broggini M
    Epigenetics; 2013 Jun; 8(6):656-65. PubMed ID: 23771052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose-escalation study of brostallicin, a minor groove binder, in combination with cisplatin in patients with advanced solid tumors.
    Caponigro F; Lorusso D; Fornari G; Barone C; Merlano M; Airoldi M; Schena M; MacArthur R; Weitman S; Jannuzzo MG; Crippa S; Fiorentini F; Petroccione A; Comis S
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):389-94. PubMed ID: 20480279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
    Lockhart AC; Howard M; Hande KR; Roth BJ; Berlin JD; Vreeland F; Campbell A; Fontana E; Fiorentini F; Fowst C; Paty VA; Lankford O; Rothenberg ML
    Clin Cancer Res; 2004 Jan; 10(2):468-75. PubMed ID: 14760067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of brostallicin (PNU-166196), a new DNA minor-groove binder, administered intravenously every 3 weeks to adult patients with metastatic cancer.
    Ten Tije AJ; Verweij J; Sparreboom A; Van Der Gaast A; Fowst C; Fiorentini F; Tursi J; Antonellini A; Mantel M; Hartman CM; Stoter G; Planting AS; De Jonge MJ
    Clin Cancer Res; 2003 Aug; 9(8):2957-64. PubMed ID: 12912942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of glutathione transferases in the mechanism of brostallicin activation.
    Pezzola S; Antonini G; Geroni C; Beria I; Colombo M; Broggini M; Marchini S; Mongelli N; Leboffe L; MacArthur R; Mozzi AF; Federici G; Caccuri AM
    Biochemistry; 2010 Jan; 49(1):226-35. PubMed ID: 19950984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of distamycin-related DNA binding anticancer drugs.
    Marchini S; Broggini M; Sessa C; D'Incalci M
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1703-14. PubMed ID: 11772279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of glutathione-dependent DNA double-strand breaks by the novel anticancer drug brostallicin.
    Guirouilh-Barbat J; Zhang YW; Pommier Y
    Mol Cancer Ther; 2009 Jul; 8(7):1985-94. PubMed ID: 19584235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
    Gelderblom H; Blay JY; Seddon BM; Leahy M; Ray-Coquard I; Sleijfer S; Kerst JM; Rutkowski P; Bauer S; Ouali M; Marreaud S; van der Straaten RJ; Guchelaar HJ; Weitman SD; Hogendoorn PC; Hohenberger P
    Eur J Cancer; 2014 Jan; 50(2):388-96. PubMed ID: 24215845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of a new potential anticancer drug: a case history.
    Cozzi P
    Farmaco; 2003 Mar; 58(3):213-20. PubMed ID: 12620417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new class of cytotoxic DNA minor groove binders: alpha-halogenoacrylic derivatives of pyrrolecarbamoyl oligomers.
    Cozzi P
    Farmaco; 2001; 56(1-2):57-65. PubMed ID: 11347968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-bromoacryloyl derivative of distamycin A (PNU 151807): a new non-covalent minor groove DNA binder with antineoplastic activity.
    Marchini S; Cirò M; Gallinari F; Geroni C; Cozzi P; D'Incalci M; Broggini M
    Br J Cancer; 1999 Jun; 80(7):991-7. PubMed ID: 10362106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of antitumor alkylating agents (AA).
    Teicher BA; Frei E
    Cancer Treat Res; 1991; 57():261-95. PubMed ID: 1686721
    [No Abstract]   [Full Text] [Related]  

  • 18. Glutathione S-transferases as regulators of kinase pathways and anticancer drug targets.
    Townsend DM; Findlay VL; Tew KD
    Methods Enzymol; 2005; 401():287-307. PubMed ID: 16399394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of a benzoic acid mustard derivative of distamycin A (FCE 24517) and related minor groove-binding distamycin analogues on the activity of major groove-binding alkylating agents.
    Coley HM; Mongelli N; D'Incalci M
    Biochem Pharmacol; 1993 Feb; 45(3):619-26. PubMed ID: 8442762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
    Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
    Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.